TScan Therapeutics, Inc. TCRX
0.34
(0.01)
(2.86%)
as of 25 Sep
- Market cap
- $23.7M
- P/E
- 0.0×
Follow TCRX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(76.44%) | (71.28%) | (80.95%) | (95.80%) | |
| (46.73%) | (43.26%) | (46.50%) | (50.09%) | ||
ROIC |
0.00% | (2,610.99%) | (5,295.51%) | (4,588.23%) | |
Return on Tangible Assets |
(84.75%) | (88.14%) | (102.80%) | (145.00%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.05) | (1.08) | (0.96) | (0.91) | |
Free Cash Flow |
(135.85) | (139.73) | (124.96) | (118.41) | |
Capital Expenditures |
(5.12) | (4.41) | (2.94) | (2.13) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(36.22%) | (43.93%) | (47.36%) | (57.58%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,465.81% | 1,105.57% | 1,163.16% | 1,364.56% | |
Selling, General and Administrative Expense of Revenue |
399.20% | 309.81% | 345.58% | 430.59% | |
Share Based Compensation of Revenue |
147.36% | 113.38% | 117.74% | 138.39% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 1.04 | 0.98 | 0.99 | |
Depreciation/Fixed assets |
0.31 | 0.33 | 0.35 | 0.37 | |
Capex/Depreciation |
(1.80) | (1.54) | (1.02) | (0.74) | |
Revenue per Share |
0.06 | 0.08 | 0.07 | 0.05 | |
Operating CF per Share |
(1.01) | (1.04) | (0.94) | (0.89) | |
Capex per Share |
(0.04) | (0.03) | (0.02) | (0.02) | |
Capex to Sales |
0.61 | 0.43 | 0.32 | 0.30 | |
Net Profit Margin |
(1,692.96%) | (1,256.81%) | (1,360.61%) | (1,655.35%) |
Columns are period end dates